FDA Approves Ivosidenib for IDH1-Mutated Cholangiocarcinoma

On August 25, 2021, Servier Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved ivosidenib for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test.

Read the FDA announcement.

Read Servier Pharmaceuticals' announcement.

Posted 8/26/2021